Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial

Denosumab (DNM) is a fully human monoclonal antibody against the receptor activator of nuclear factor kappa-B ligand (RANKL) that has been licensed for the treatment of different types of osteoporosis. However, the prospective data for the evaluation of DNM efficacy on transfusion-dependent thalasse...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Blood Adv
Hlavní autoři: Voskaridou, Ersi, Ntanasis-Stathopoulos, Ioannis, Papaefstathiou, Athanasios, Christoulas, Dimitrios, Dimopoulou, Maria, Repa, Konstantina, Papatheodorou, Athanasios, Peppa, Melpomeni, Terpos, Evangelos
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2018
Témata:
Red Cells, Iron, and Erythropoiesis
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6234378/
https://ncbi.nlm.nih.gov/pubmed/30381400
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018023085
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky